Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer

BACKGROUND: MVA-BN-brachyury-TRICOM is a recombinant vector-based therapeutic cancer vaccine designed to induce an immune response against brachyury. Brachyury, a transcription factor overexpressed in advanced cancers, has been associated with treatment resistance, epithelial-to-mesenchymal transiti...

Descripción completa

Detalles Bibliográficos
Autores principales: DeMaria, Peter J, Lee-Wisdom, Katherine, Donahue, Renee N, Madan, Ravi A, Karzai, Fatima, Schwab, Angie, Palena, Claudia, Jochems, Caroline, Floudas, Charalampos, Strauss, Julius, Marté, Jennifer L, Redman, Jason Mark, Dombi, Eva, Widemann, Brigitte, Korchin, Borys, Adams, Tatiana, Pico-Navarro, Cesar, Heery, Christopher, Schlom, Jeffrey, Gulley, James L, Bilusic, Marijo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420671/
https://www.ncbi.nlm.nih.gov/pubmed/34479925
http://dx.doi.org/10.1136/jitc-2021-003238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420671/
https://www.ncbi.nlm.nih.gov/pubmed/34479925
http://dx.doi.org/10.1136/jitc-2021-003238

Ejemplares similares